Little Evelo sees big promise in its first cut of data from a tiny study on atopic dermatitis
Anyone putting together an early-stage trial involving 24 patients with a big-market disease like atopic dermatitis wants to know one thing: Do they have a drug that’s active, with real potential as a therapy?
Evelo $EVLO just posed that question, and the answer in the data, says chairman David Epstein, is yes.
“The drug starts to work at 2 weeks,” Epstein says as he looks at the data. “That’s really fast.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.